Trial
NCT04271306
Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania.
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Oxford
Collaborators
Ifakara Health Institute
Condition
Malaria,Falciparum
Intervention
Pfs25-IMX313 (10ug)/Matrix-M (50ug)
Why stopped
Due to significant delays in receiving local regulatory approval to extend the shelf-life of the IMP.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-01-27